Some thoughts on this policy: It vaguely refers to prices that are “not reasonable” as a new criterion for invalidating drug patents, which will now become a factor in IP diligence for VCs and drug makers. If a program is heavily reliant on NIH funding, investors might devalue its existing patents, leading to less funding for NIH-derived molecules. Ultimately, the policy could diminish the societal value of NIH investments, as more NIH-funded research may remain unused, and prompt some investors to look harder for molecules developed outside the U.S.
Moreover, investors and drug companies tend to overestimate, rather than underestimate, these kinds of policy risks, incorporating uncertainty about its application in the future. They often assume the worst, magnifying the impact of a policy misstep.
Undoubtedly, too many patients are priced out of necessary drugs, with some prices unreasonable relative to the benefits. Some of the growing hardship stems from the progressive weakening of drug insurance, exacerbated by the ACA’s promotion of skinny and closed drug formularies, leaving more consumers without coverage for many drugs.
The administration could take pro-competitive steps to lower consumer costs, such as transitioning Medicare Part B to a competitively bid system to encourage price competition, similar to Part D. Other measures include reducing barriers to generic entry, especially for complex drugs; creating a streamlined market route for second-to-market drug innovations to reduce monopolies; establishing a pathway for truly interchangeable biosimilars; focus on policies that will reduce development costs by modernizing clinical trials; and create a more explicit path for drugs that can be dispensed by a pharmacist or in a pharmacy, which can reduce acquisition costs for patients who are out-of-pocket for their drug expenses, and offer a lower cost option to a competing, prescription product.
Unfortunately, these kinds of pro-competitive policies have not been a focus in recent years.